The IDPC membership share insights on progress and setbacks in drug policy reform in 47 countries.

IDPC, TB/HIV Care and ARASA demonstrate how drug policy reform is a sustainable development issue that African countries need to urgently address to achieve the SDGs.

The Harm Reduction Consortium presents the first edition of the Global Drug Policy Index, which documents, measures and compares national-level drug policies against the UN Common Position on drugs.

This short document serves as a practical guide for civil society on possible ways to use the Model Drug Law in advancing drug policy reform in West Africa and beyond.

This ‘explainer’ aims to provide a more accessible summary of the key elements included in the West Africa Model Drug Law.

IDPC draws lessons from the challenges of tobacco control, including in relation to corporate capture, to inform the design of equitable, inclusive and sustainable cannabis legal regulation.

IDPC offers a historical analysis of civil society advocacy for drug policy reform at the UN, assessing gains, challenges and insight on how the latter have been generally overcome.

PRI and IDPC detail how policymakers and practitioners in the criminal legal system can reduce the imprisonment of women for drug-related offences in line with international standards.

The 64th session of the CND was marked by the increase in prominence of health and human rights narratives, the proceedings' 'hybrid format' and a welcome long-overdue shift in the US stance on harm reduction.

IDPC and HRI document disruptions and challenges, as well as positive developments faced by harm reduction in relation to the COVID-19 pandemic.

IDPC and Instituto RIA argue that blanket prohibitions on practices to alter one's consciousness constitute unlawful limitations on the right to the freedom of thought.

IDPC documents failures in the provision of menstrual products by prison and state systems during the pandemic emergency.

The 1st Brandenburg Forum provided a trusted space for important discussion and debate to strengthen the drug policy focus within the key health and human rights bodies in Geneva.

IDPC highlights several systemic issues prevalent in human rights abuses directed at those held against their will in drug treatment centres.

Hill, Fehér, and Bridge outline civil society engagement processes and encourage practitioners to take a more active role.

FEDITO BLX and IDPC make recommendations for Belgium's UPR, focusing on adopting a public health approach, decriminalising people who use drugs and providing a clear legal framework for drug consumption rooms.

IDPC provides a critique of the UNODC Strategy 2021-2025 with a focus on two critical issues: the exclusion of civil society and communities from the development and approval of the document; and the departure from the policy priorities established in the 2018 UN system Common Position on drugs.

IDPC takes stock of progress made on the implementation of the recommendations included in the UNGASS Outcome Document, focusing on six critical areas: public health, development, human rights, civil society engagement, UN agency collaboration and cooperation, and drug policy evaluation.

IDPC and TNI provide an overview of the evolution of the UN-agreed language on key drug policy issues for the last three decades.

Based on experiences from dozens of countries across the globe, IDPC outlines key lessons learned from civil society advocacy during and after the COVID-19 pandemic.